-
Stem cell banking an unclear path for regenerative medicine: 4 notes
LifeVault Bio's GoodCell kit allows customers to bank their stem cells for future use, STAT reports, but not all stem cell researchers are on board. -
Fidelity International invests $5.2M in stem cell, regenerative medicine company — 3 insights
Global asset manager Fidelity International invested $5.2 million in Cynata Therapeutics, an Australian stem cell and regenerative medicine company, Business Insider Australia reports. -
The global spine biologics market to grow at CAGR of 4.1% through 2022: 3 things to know
The global spine biologics market is forecasted to grow at a compound annual growth rate of 4.09 percent between 2018 and 2022, according to a Technavio report. -
DiscGenics treats 1st patient in degenerative disc disease clinical trial: 5 things to know
DiscGenics principal investigator Domagoj Coric, MD, of Carolina Neurosurgery and Spine Associates in Charlotte, N.C., treated the first patient in the phase 1/phase 2 clinical trial of IDCT. -
3 things to know about Organogenesis
Organogenesis is a regenerative medicine company based in Canton, Mass., focused on developing products for the wound care, surgical and sports medicine markets. -
Study: Single-injection durolane hylauronic acid safe, effective treatment for knee osteoarthritis
Treating knee arthritis with NASHA (durolane hyaluronic acid) is a safe and effective procedure, according to a study in Open Access Rheumatology: Research and Reviews. -
Who are the 14 major players in the global spine biologics market?
Here are the 14 major players in the global spine biologics market, according to an E Market Research report. -
Cerapedics i-FACTOR yields 50% fusion rate vs. 20% for allograft at 1-year follow-up — 3 insights
Mikkel O. Andersen, MD, of Middelfart Hospital in Denmark, reported results from the IVANOS study investigating Cerapedics' i-FACTOR Peptide Enhanced Bone Graft. -
3 things to know about Burst Biologics
Burst Biologics, based in Boise, Idaho, is a regenerative medicine company. -
Patients duped by non-FDA approved stem cell marketing: 8 things to know
Orthopedic surgeons continue to express concerns over various stem cell treatments being offered to patients, according to Contact7. -
Crowdfunding for stem cell treatments may spread misinformation: 4 insights
Insurers will not usually pay for unproven stem cell treatments, so patients seeking those interventions must pay out-of-pocket or use social media to receive donations, a practice known as crowdfunding. Medical crowdfunding campaigns may convey misleading messages about stem cell-based interventions, according to a JAMA study. -
4 things to know about NuVasive's AttraX Putty
NuVasive's biologics portfolio includes AttraX Putty. -
Target stem cells to stop osteoarthritis progression, study suggests: 3 insights
Osteoarthritis-mesenchymal stem cells may drive cartilage degeneration pathogenesis and should be targeted in osteoarthritis therapy, according to a study in Scientific Reports. -
Stem cell-derived neurons survive grafting into spinal cord injury in animal study: 3 things to know
Researchers successfully grafted induced pluripotent stem cell-derived neural precursor cells into the spinal cords of pigs with and without spinal cord injury with only temporary immunosuppression, according to a study in Science Translational Medicine. -
FDA seeks to shut down stem cell clinics offering unapproved treatments: 5 insights
The U.S. Department of Justice filed lawsuits to shut down stem cell clinics in Florida and California that marketed unapproved stem cell treatments, the Los Angeles Times reports. -
Transplanted spinal cord stem cells may help ALS sufferers: 4 insights
Transplanted human spinal cord-derived neural stem cells may stabilize functioning in amyotrophic lateral sclerosis patients, according to a study in the Annals of Clinical and Translational Neurology. -
Global spine biologics market to hit $2.7B by 2023: 3 observations
The global spine biologics market will likely grow at a compound annual growth rate of 4.5 percent between 2018 and 2023, based on a Market.biz report, according to Business News. -
6 things to know about Bone Biologics
Bone Biologics, based in Burlington, Mass., is a publicly traded company focused on orthobiologic solutions. -
Dr. Luga Podesta on stem cells in orthopedics, 'a new frontier in medicine'
Luga Podesta, MD, is a sports medicine and regenerative orthopedic specialist at Bluetail Medical Group in Naples, Fla. He was the lead author in a 2013 study in The American Journal of Sports Medicine which demonstrated that platelet-rich plasma can effectively treat partial UCL tears in athletes. In a recent interview with Becker's Spine Review, Dr. Podesta spoke about the possibilities and pitfalls of stem cell therapies in orthopedics and trends in regenerative medicine. -
Who are the 15 major players in the global orthobiologics market?
The global orthobiologics market is expected to grow from $4.66 billion in 2017 to reach $8.06 billion by 2023, increasing at a 5.7 percent compound annual growth rate, according to a Market.Biz report.
Page 34 of 36